The Expertise of Bio Elpida in the Production of GMP Cell Bank
Primary cell bank, research bank, MCB, WCB et End of Product Cell Bank

Bio Elpida proposes the production of prokaryote and eukaryote cell banks under GMP conditions. This production includes characterization and QC control of the cell banks.

The banks proposed are:
  • Primary Banks,
  • Research Banks,
  • Master Cell Bank,
  • Working Cell Bank,
  • End of Production Cell Bank.

Cell bank production was declared and is part of the activity of the establishment authorized by the ANSM (French Medical Regulatory Agency) for producing MPUP. These operations are performed in the pharmaceutical zone and are compliant with current regulation and guidelines (ICH Q5A, Q5B, Q5D, CFR21 part 680, cGMP annexe 3…).

Bio Elpida

Founded in 2009, Bio Elpida is a Biotechnology Contract Manufacturing Company specialised in the development and manufacturing of innovative cell therapies.

The expertise of the company covers 3 areas:
In these areas, Bio Elpida offers services that include:
Bio Elpida is the first French laboratory certified by the French Health Authorities (MSNA) as a Pharmaceutical Company and authorised to manufacture Active Pharmaceutical Ingredients for experimental biological pharmaceuticals.

Bio Elpida - 97 allée Alexandre Borodine - Bâtiment 5 Cèdre 1 - 69800 Saint Priest - FRANCE - Phone: +33 (0)4 78 47 02 70 - Mail: infos@bio-elpida.com
© Bio Elpida. All Rights Reserved - Legal information - Web site by: Estium-Concept
  • Your CMO for
    Innovative Therapy
    SEARCH
    INNOVATE
    ACHIEVE
  • Your CMO for
    Innovative Therapy
    SEARCH
    INNOVATE
    ACHIEVE
  • Your CMO for
    Innovative Therapy
    SEARCH
    INNOVATE
    ACHIEVE
  •  
  •  
  •